The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.
In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.
The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.
Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...
NEW YORK – The BC Cancer Foundation in Vancouver, British Columbia, said it aims to raise C$6.8 million (US$4.8 million) to expand its immunotherapy research program, which is focused on developing ...
NEW YORK – Aptose Biosciences on Thursday said it has entered into a common share purchase agreement with an institutional investor, which it expects will bring in around $2.1 million in gross ...
NEW YORK – Restore Vision on Thursday said it has treated the first patient in a Phase I/II trial with RV-001, the company's lead gene therapy that it is developing for retinitis pigmentosa (RP). The ...
In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback